AP-1 confers resistance to anti-cancer therapy by activating XIAP

The underlying cause of treatment failure in many cancer patients is intrinsic and acquired resistance to chemotherapy. Recently, histone deacetylase (HDAC) inhibitors have developed into a promising cancer treatment. However, resistance mechanism induced by HDAC inhibitors remains largely unknown....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuan, Wan, Guo-Hui, Wu, Ying-Min, Wang, Hong-Sheng, Wang, Hai-Fang, Zhang, Ge, Lu, Lin-Lin, Li, Zi-Qian, Chan, Ka-Ying, Zhou, Yan, Cai, Shao-Hui, Qi, Yi-Fei, Du, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865658/
https://www.ncbi.nlm.nih.gov/pubmed/29581832
http://dx.doi.org/10.18632/oncotarget.23897
_version_ 1783308714038525952
author Wang, Yuan
Wan, Guo-Hui
Wu, Ying-Min
Wang, Hong-Sheng
Wang, Hai-Fang
Zhang, Ge
Lu, Lin-Lin
Li, Zi-Qian
Chan, Ka-Ying
Zhou, Yan
Cai, Shao-Hui
Qi, Yi-Fei
Du, Jun
author_facet Wang, Yuan
Wan, Guo-Hui
Wu, Ying-Min
Wang, Hong-Sheng
Wang, Hai-Fang
Zhang, Ge
Lu, Lin-Lin
Li, Zi-Qian
Chan, Ka-Ying
Zhou, Yan
Cai, Shao-Hui
Qi, Yi-Fei
Du, Jun
author_sort Wang, Yuan
collection PubMed
description The underlying cause of treatment failure in many cancer patients is intrinsic and acquired resistance to chemotherapy. Recently, histone deacetylase (HDAC) inhibitors have developed into a promising cancer treatment. However, resistance mechanism induced by HDAC inhibitors remains largely unknown. Here we report that a HDAC inhibitor, JNJ-2648158 induced transcription of XIAP by activating AP-1 expression, which conferring resistance to chemotherapeutics. Our results showed that high expression of c-Fos caused by HDAC inhibitor promoted AP-1 formation during acquired resistance towards chemo-drugs, indicating an extremely poor clinical outcome in breast cancers and liver cancers. Our study reveals a novel regulatory mechanism towards chemo-drug resistance, and suggests that XIAP may serve as a potential therapeutic target in those chemo-resistant cancer cells.
format Online
Article
Text
id pubmed-5865658
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-58656582018-03-26 AP-1 confers resistance to anti-cancer therapy by activating XIAP Wang, Yuan Wan, Guo-Hui Wu, Ying-Min Wang, Hong-Sheng Wang, Hai-Fang Zhang, Ge Lu, Lin-Lin Li, Zi-Qian Chan, Ka-Ying Zhou, Yan Cai, Shao-Hui Qi, Yi-Fei Du, Jun Oncotarget Research Paper The underlying cause of treatment failure in many cancer patients is intrinsic and acquired resistance to chemotherapy. Recently, histone deacetylase (HDAC) inhibitors have developed into a promising cancer treatment. However, resistance mechanism induced by HDAC inhibitors remains largely unknown. Here we report that a HDAC inhibitor, JNJ-2648158 induced transcription of XIAP by activating AP-1 expression, which conferring resistance to chemotherapeutics. Our results showed that high expression of c-Fos caused by HDAC inhibitor promoted AP-1 formation during acquired resistance towards chemo-drugs, indicating an extremely poor clinical outcome in breast cancers and liver cancers. Our study reveals a novel regulatory mechanism towards chemo-drug resistance, and suggests that XIAP may serve as a potential therapeutic target in those chemo-resistant cancer cells. Impact Journals LLC 2018-01-03 /pmc/articles/PMC5865658/ /pubmed/29581832 http://dx.doi.org/10.18632/oncotarget.23897 Text en Copyright: © 2018 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Wang, Yuan
Wan, Guo-Hui
Wu, Ying-Min
Wang, Hong-Sheng
Wang, Hai-Fang
Zhang, Ge
Lu, Lin-Lin
Li, Zi-Qian
Chan, Ka-Ying
Zhou, Yan
Cai, Shao-Hui
Qi, Yi-Fei
Du, Jun
AP-1 confers resistance to anti-cancer therapy by activating XIAP
title AP-1 confers resistance to anti-cancer therapy by activating XIAP
title_full AP-1 confers resistance to anti-cancer therapy by activating XIAP
title_fullStr AP-1 confers resistance to anti-cancer therapy by activating XIAP
title_full_unstemmed AP-1 confers resistance to anti-cancer therapy by activating XIAP
title_short AP-1 confers resistance to anti-cancer therapy by activating XIAP
title_sort ap-1 confers resistance to anti-cancer therapy by activating xiap
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865658/
https://www.ncbi.nlm.nih.gov/pubmed/29581832
http://dx.doi.org/10.18632/oncotarget.23897
work_keys_str_mv AT wangyuan ap1confersresistancetoanticancertherapybyactivatingxiap
AT wanguohui ap1confersresistancetoanticancertherapybyactivatingxiap
AT wuyingmin ap1confersresistancetoanticancertherapybyactivatingxiap
AT wanghongsheng ap1confersresistancetoanticancertherapybyactivatingxiap
AT wanghaifang ap1confersresistancetoanticancertherapybyactivatingxiap
AT zhangge ap1confersresistancetoanticancertherapybyactivatingxiap
AT lulinlin ap1confersresistancetoanticancertherapybyactivatingxiap
AT liziqian ap1confersresistancetoanticancertherapybyactivatingxiap
AT chankaying ap1confersresistancetoanticancertherapybyactivatingxiap
AT zhouyan ap1confersresistancetoanticancertherapybyactivatingxiap
AT caishaohui ap1confersresistancetoanticancertherapybyactivatingxiap
AT qiyifei ap1confersresistancetoanticancertherapybyactivatingxiap
AT dujun ap1confersresistancetoanticancertherapybyactivatingxiap